Kuros Biosciences (KURN) Price & Analysis

Compare

4 Followers

KURN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF14.00 - CHF32.00

Previous CloseN/A

Volume98.33K

Average Volume (3M)166.78K

Market Cap

CHF1.08B

Enterprise ValueCHF1.03B

Total Cash (Recent Filing)CHF17.90M

Total Debt (Recent Filing)CHF1.79M

Price to Earnings (P/E)―

Beta1.59

Next Earnings

Mar 10, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding38,936,220

10 Day Avg. Volume212,395

30 Day Avg. Volume166,783

Financial Highlights & Ratios

PEG Ratio2.90

Price to Book (P/B)13.52

Price to Sales (P/S)10.51

P/FCF Ratio391.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF32.50

Price Target Upside8.34% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Kuros Biosciences News

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences is addressing media inquiries regarding the resignation...

22d ago

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

1M ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

2M ago

Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences reported a 78% increase in total medical...

2M ago

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported an 82% year-over-year increase...

6M ago

Kuros Biosciences Reports Strong Revenue Growth in 2024

Kuros Biosciences ( ($CSBTF) ) has released its Q4 earnings. Here is a breakdown of the information Kuros...

7M ago

KURN FAQ

What was Kuros Biosciences’s price range in the past 12 months?

Kuros Biosciences lowest stock price was CHF14.00 and its highest was CHF32.00 in the past 12 months.

What is Kuros Biosciences’s market cap?

Kuros Biosciences’s market cap is CHF1.08B.

When is Kuros Biosciences’s upcoming earnings report date?

Kuros Biosciences’s upcoming earnings report date is Mar 10, 2026 which is in 151 days.

How were Kuros Biosciences’s earnings last quarter?

Kuros Biosciences released its earnings results on Aug 14, 2025. The company reported -CHF0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.052.

Is Kuros Biosciences overvalued?

According to Wall Street analysts Kuros Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences pay dividends?

Kuros Biosciences does not currently pay dividends.

What is Kuros Biosciences’s EPS estimate?

Kuros Biosciences’s EPS estimate is 0.

How many shares outstanding does Kuros Biosciences have?

Kuros Biosciences has 38,936,220 shares outstanding.

What happened to Kuros Biosciences’s price movement after its last earnings report?

Kuros Biosciences reported an EPS of -CHF0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.311%.

Which hedge fund is a major shareholder of Kuros Biosciences?

Currently, no hedge funds are holding shares in CH:KURN

Company Description

Kuros Biosciences

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Kuros Biosciences (KURN) Earnings & Revenues

Historic Earnings Reports

KURN Company Deck

KURN Earnings Call

Q2 2025

0:00 / 0:00

KURN Stock 12 Month Forecast

Average Price Target

CHF32.50

▲(8.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"CHF15","24":"CHF24","33":"CHF33","19.5":"CHF19.5","28.5":"CHF28.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.502752373,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.502752373,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.502752373,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF32.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,19.5,24,28.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,25.577134797923076,26.154269595846152,26.731404393769232,27.308539191692308,27.885673989615384,28.46280878753846,29.039943585461536,29.617078383384616,30.194213181307692,30.771347979230768,31.348482777153848,31.92561757507692,{"y":32.502752373,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,25.577134797923076,26.154269595846152,26.731404393769232,27.308539191692308,27.885673989615384,28.46280878753846,29.039943585461536,29.617078383384616,30.194213181307692,30.771347979230768,31.348482777153848,31.92561757507692,{"y":32.502752373,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,25.577134797923076,26.154269595846152,26.731404393769232,27.308539191692308,27.885673989615384,28.46280878753846,29.039943585461536,29.617078383384616,30.194213181307692,30.771347979230768,31.348482777153848,31.92561757507692,{"y":32.502752373,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.9,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.86,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.85,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.35,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.95,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.1,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.38,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.88,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >